Skip to content

The Correlation and Mechanism between the Endocannabinoid System and Treg/Th17 Imbalance in Septic Patients: A Prospective Cohort Study

The Correlation and Mechanism between the Endocannabinoid System and Treg/Th17 Imbalance in Septic Patients: A Prospective Cohort Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112641
Enrollment
Unknown
Registered
2025-11-18
Start date
2025-11-18
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Persistent Inflammation-Immunosuppression Catabolism Syndrome:None

Sponsors

Shiyan Taihe Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: **Healthy Control (HC) Group:** 1. Age >= 65 years; 2. No active infection, immune diseases, or related medication history; 3. Written informed consent obtained from the patient or their legal representative. **Sepsis Patients:** 1. Age >= 65 years; 2. Meet the Sepsis 3.0 International Consensus diagnostic criteria: Infection + SOFA score (Cardiovascular SOFA =1 point, or SOFA score =2 points in other organ systems); 3. Written informed consent obtained from the patient or their legal representative. **Persistent Inflammation-Immunosuppression Catabolism Syndrome (PICS) Patients:** 1. ICU stay >= 14 days; 2. C-reactive protein (CRP) > 150 mg/dL; 3. Lymphocyte count (LYM) 10% during the hospital stay or Body Mass Index (BMI) < 18 kg/m².

Exclusion criteria

Exclusion criteria: 1. Individuals with immune deficiency; 2. Patients receiving immunomodulatory therapy: including chronic use of prednisone (or equivalent corticosteroids), chemotherapy, or biological immunomodulators (e.g., immunosuppressants); 3. Other factors: Patients with sepsis attributed to other causes such as cancer or trauma (the study focuses specifically on sepsis following bacterial infection).

Design outcomes

Primary

MeasureTime frame
endocannabinoid expression level;Treg/Th17 cell ;

Countries

China

Contacts

Public ContactKe Xianting

Shiyan Taihe Hospital

xiantingke@126.com+86 187 7205 5151

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026